Abbott Laboratories (NYSE:ABT) shares traded 0.55% higher at $133.58 on Wall Street last session.
ABT stock price is now 2.50% away from the 50-day moving average and 9.57% away from the 200-day moving average. The market capitalization of the company currently stands at $232.41B.
With the price target of $130, Oppenheimer recently initiated with Outperform rating for Abbott Laboratories (NYSE: ABT). On September 19, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $131, while ‘Edward Jones’ rates the stock as ‘Hold’
In other news, Blount Sally E., Director sold 2,600 shares of the company’s stock on Apr 30 ’25. The stock was sold for $337,116 at an average price of $129.66. Upon completion of the transaction, the Director now directly owns 34,058 shares in the company, valued at $4.55 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 30 ’25, Director SALLY E BLOUNT bought 2,600 shares of the business’s stock. A total of $337,116 was incurred on buying the stock at an average price of $129.66. A total of 0.67% of the company’s stock is owned by insiders.
During the past 12 months, Abbott Laboratories has had a low of $99.71 and a high of $141.23. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 1.78, and a quick ratio of 1.27.
The net profit margin was 31.72% and return on equity was 30.66% for ABT. The company reported revenue of $10.36 billion for the quarter, compared to $9.96 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.95 percent.
